1. Macrolide antibiotics exert their bacteriostatic effect by binding to bacterial ribosomes. Which of the following correctly identifies both the ribosomal subunit targeted and the specific molecular consequence of macrolide binding?
A) Binding to the 30S subunit, preventing formation of the initiation complex between mRNA and the ribosome
B) Binding to the 23S rRNA of the 50S subunit, blocking translocation of the peptidyl-tRNA from the A site to the P site
C) Binding to the 30S subunit at the A site, causing misreading of the mRNA codon and incorporation of incorrect amino acids
D) Binding to the 50S subunit at the peptidyl transferase center, directly inhibiting the peptide bond-forming reaction between amino acids
E) Binding to the 23S rRNA of the 50S subunit, preventing association of the 30S and 50S subunits into a functional 70S ribosome
ANSWER: B
Rationale:
Macrolides bind specifically to domain V of the 23S rRNA component of the 50S ribosomal subunit, positioning within the nascent peptide exit tunnel just proximal to the peptidyl transferase center. The primary functional consequence is blockade of translocation — the movement of the peptidyl-tRNA from the acceptor (A) site to the peptidyl (P) site after each peptide bond formation step. By obstructing the exit tunnel, macrolides stall elongating peptide chains after synthesis of only a few amino acids, arresting protein synthesis and producing a bacteriostatic effect against most susceptible organisms.
Option A: Option A is incorrect because the 30S subunit is the target of aminoglycosides and tetracyclines, not macrolides; aminoglycosides cause misreading at the 30S A site, while tetracyclines block aminoacyl-tRNA entry to the 30S A site.
Option C: Option C is incorrect for the same reason — codon misreading is an aminoglycoside effect at the 30S subunit, not a macrolide mechanism.
Option D: Option D is incorrect because macrolides do not directly inhibit the peptidyl transferase reaction itself; they act downstream by obstructing the peptide exit tunnel and blocking translocation rather than preventing peptide bond formation at the transferase center.
Option E: Option E is incorrect because macrolides do not prevent 70S ribosome assembly; that mechanism is characteristic of linezolid and other oxazolidinones, which inhibit formation of the initiation complex at an earlier step in ribosome assembly.
2. Azithromycin differs structurally from erythromycin and clarithromycin in a way that fundamentally alters its pharmacokinetic behavior. Which of the following best describes the structural feature that distinguishes azithromycin from the other major macrolides and the pharmacokinetic consequence most directly attributable to that feature?
A) Azithromycin contains a 16-membered lactone ring, which increases acid stability and allows twice-daily dosing compared to the four-times-daily schedule required for erythromycin
B) Azithromycin is a 6-O-methyl derivative of erythromycin, a modification that improves acid stability and generates an active 14-hydroxy metabolite that extends its antibacterial spectrum to include Haemophilus influenzae
C) Azithromycin contains a fluorine atom at position 8 of the lactone ring, which reduces CYP3A4 binding affinity and accounts for its minimal cytochrome P450 inhibition compared to erythromycin
D) Azithromycin is an azalide — a 15-membered ring macrolide in which a nitrogen atom is incorporated into the lactone ring — a modification that produces tissue concentrations 10 to 100 times higher than concurrent serum levels and a tissue half-life of approximately 68 hours
E) Azithromycin undergoes extensive hepatic demethylation by CYP3A4, generating multiple active metabolites that accumulate in phagocytic cells and account for its prolonged post-antibiotic effect
ANSWER: D
Rationale:
Azithromycin is classified as an azalide rather than a true macrolide because its 15-membered lactone ring contains a nitrogen atom inserted into the ring structure — a modification from the 14-membered rings of erythromycin and clarithromycin. This structural change profoundly alters tissue distribution: azithromycin is avidly taken up by phagocytic cells including alveolar macrophages, polymorphonuclear neutrophils, and monocytes, achieving intracellular tissue concentrations 10 to 100 times higher than simultaneous serum levels. The resulting tissue half-life of approximately 68 hours supports once-daily dosing and short-course regimens, including single-dose therapy for Chlamydia trachomatis.
Option A: Option A is incorrect because azithromycin has a 15-membered, not 16-membered, ring; 16-membered macrolides are a distinct subclass (spiramycin, josamycin) not in clinical use in the United States.
Option B: Option B is incorrect because the 6-O-methyl derivative with an active 14-hydroxy metabolite describes clarithromycin, not azithromycin; the 14-hydroxyclarithromycin metabolite specifically adds H. influenzae coverage.
Option C: Option C is incorrect because azithromycin's minimal CYP3A4 inhibition is not due to a fluorine substituent; it results from the fact that azithromycin is not significantly demethylated by CYP3A4 and therefore does not form the nitrosoalkane-Fe²⁺ inhibitory complex that erythromycin and clarithromycin produce.
Option E: Option E is incorrect because azithromycin is not extensively metabolized by CYP3A4 to active metabolites; it is excreted primarily unchanged in bile, and its intracellular accumulation reflects active transport rather than metabolic activation.
3. Erythromycin was formulated as enteric-coated tablets and as ester derivatives (stearate, ethylsuccinate) rather than as a simple oral salt. Which of the following correctly identifies the pharmacological basis for these formulation strategies and their primary limitation?
A) Erythromycin is a weak base that undergoes significant acid-catalyzed degradation in the gastric environment; enteric coatings and ester formulations delay dissolution until the drug reaches the less acidic small intestine, but oral bioavailability remains variable, averaging approximately 35 to 65% depending on formulation and fed state
B) Erythromycin undergoes extensive first-pass hepatic metabolism by CYP3A4 in the gut wall and liver, reducing systemic exposure; enteric coatings bypass portal circulation by promoting lymphatic absorption, achieving bioavailability approaching 90%
C) Erythromycin is highly lipophilic and precipitates as an insoluble complex at gastric pH; ester formulations chelate gastric acid to maintain drug solubility, but the chelate must be hydrolyzed in the small intestine before absorption can occur
D) Erythromycin is unstable in the presence of bile salts secreted into the duodenum; enteric coatings protect the drug until it reaches the ileum, where bile salt concentrations are lower and drug absorption is most efficient
E) Erythromycin binds irreversibly to gastric mucin at acidic pH, reducing the fraction available for absorption; ester formulations mask the polar hydroxyl groups responsible for mucin binding, improving delivery to the intestinal epithelium
ANSWER: A
Rationale:
Erythromycin is a weak base that is acid-labile, meaning it undergoes significant chemical degradation — specifically, acid-catalyzed intramolecular ketal formation and other rearrangements — when exposed to the low pH of the stomach. This instability reduces the amount of intact drug available for absorption. Enteric-coated formulations delay tablet dissolution until the drug exits the stomach and enters the less acidic small intestine, while ester forms (erythromycin stearate, ethylsuccinate) provide some degree of protection from acid hydrolysis. Despite these strategies, oral bioavailability remains variable and averages approximately 35 to 65%, reflecting ongoing variability in gastric emptying time, fed state, and formulation-specific dissolution behavior.
Option B: Option B is incorrect because enteric coatings do not promote lymphatic absorption or bypass portal circulation; they simply delay dissolution to a higher-pH environment. Erythromycin bioavailability does not approach 90% with any oral formulation.
Option C: Option C is incorrect because erythromycin is not highly lipophilic in a way that causes precipitation as an insoluble complex, and ester formulations do not function by chelating gastric acid; the mechanism of acid instability is chemical degradation at low pH, not solubility-driven precipitation.
Option D: Option D is incorrect because bile salt instability is not the primary problem with erythromycin oral delivery; the acid lability in the stomach — before the drug even reaches the duodenum where bile salts are concentrated — is the dominant formulation challenge.
Option E: Option E is incorrect because binding to gastric mucin is not the mechanism of erythromycin acid instability, and ester formulations do not function by masking hydroxyl groups to reduce mucin binding.
4. A 58-year-old man with a history of a renal transplant is maintained on tacrolimus (a calcineurin inhibitor) and develops community-acquired pneumonia requiring antibiotic therapy. The prescribing clinician must choose among macrolide options. Which of the following correctly ranks macrolide agents by their cytochrome P450 3A4 (CYP3A4) inhibitory potency and identifies the safest choice for this patient?
A) Azithromycin is the most potent CYP3A4 inhibitor among macrolides because its nitrogen-containing ring forms a stable complex with the ferrous iron of CYP3A4; it should be avoided in this transplant patient
B) All three major macrolides — erythromycin, clarithromycin, and azithromycin — are equally potent mechanism-based CYP3A4 inhibitors; the choice between them should be based on spectrum of activity rather than drug interaction risk
C) Erythromycin is the most potent macrolide CYP3A4 inhibitor, acting via irreversible mechanism-based inhibition through a nitrosoalkane-Fe²⁺ complex; clarithromycin is also a significant inhibitor; azithromycin produces negligible CYP3A4 inhibition and is the preferred macrolide in this patient
D) Clarithromycin is the most potent macrolide CYP3A4 inhibitor because its 14-hydroxy active metabolite forms an irreversible adduct with CYP3A4; erythromycin and azithromycin have equivalent and lower inhibitory potency
E) Azithromycin should be avoided in this patient because its prolonged tissue half-life of 68 hours results in sustained CYP3A4 inhibition for weeks after the antibiotic course is completed, posing greater long-term interaction risk than erythromycin
ANSWER: C
Rationale:
Among the three major macrolides, erythromycin is the most potent CYP3A4 inhibitor. It acts as a mechanism-based (irreversible) inhibitor: erythromycin is metabolized by CYP3A4 to a nitrosoalkane intermediate that forms a stable, inactive complex with the ferrous (Fe²⁺) form of the enzyme, permanently inactivating that enzyme molecule and requiring new CYP3A4 synthesis for recovery. Clarithromycin operates by a similar mechanism and is a significant CYP3A4 inhibitor, though somewhat less potent than erythromycin. Azithromycin, because it is not significantly demethylated by CYP3A4, does not form the inhibitory nitrosoalkane complex and produces negligible CYP3A4 inhibition at clinical doses. In a transplant patient on tacrolimus — a narrow-therapeutic-index CYP3A4 substrate — erythromycin or clarithromycin would substantially elevate tacrolimus levels, risking nephrotoxicity; azithromycin is the macrolide of choice.
Option A: Option A is incorrect because azithromycin is the least potent CYP3A4 inhibitor among the three macrolides, not the most potent, and its nitrogen-containing ring does not form an inhibitory CYP3A4 complex.
Option B: Option B is incorrect because the three macrolides differ substantially in CYP3A4 inhibitory potency; they are not equivalent, and azithromycin's minimal inhibition is a clinically important distinction.
Option D: Option D is incorrect because clarithromycin's active 14-hydroxy metabolite does not form an irreversible CYP3A4 adduct; both erythromycin and clarithromycin act through the nitrosoalkane mechanism, with erythromycin being more potent.
Option E: Option E is incorrect because azithromycin's prolonged tissue half-life reflects tissue accumulation, not CYP3A4 inhibition; azithromycin does not produce sustained CYP3A4 inhibition and is the preferred choice precisely because of its minimal interaction profile.
5. A gastroenterologist considers using low-dose erythromycin for a patient with diabetic gastroparesis. A medical student asks why an antibiotic is being used for a motility disorder. Which of the following best explains the pharmacological mechanism underlying erythromycin's prokinetic effect and why azithromycin causes less gastrointestinal intolerance than erythromycin?
A) Erythromycin inhibits acetylcholinesterase in the myenteric plexus, increasing local acetylcholine concentrations and stimulating muscarinic M3 receptors on GI smooth muscle; azithromycin does not penetrate the myenteric plexus and therefore lacks this effect
B) Erythromycin blocks dopamine D2 receptors in the chemoreceptor trigger zone and gastric antrum, accelerating gastric emptying; azithromycin lacks D2 receptor affinity and therefore has no effect on gastric motility
C) Erythromycin activates 5-HT4 (serotonin type 4) receptors on enteric neurons, stimulating release of acetylcholine from the myenteric plexus and coordinating peristaltic contractions; azithromycin has lower 5-HT4 receptor affinity and therefore produces less motility stimulation
D) Erythromycin directly relaxes the lower esophageal sphincter by activating nitric oxide synthase in smooth muscle, allowing more rapid passage of gastric contents; azithromycin does not activate smooth muscle nitric oxide synthase at therapeutic concentrations
E) Erythromycin is a potent agonist of motilin receptors in the GI tract; motilin is an enteric hormone that stimulates gastric and small bowel contractions during the interdigestive migrating motor complex, accelerating gastric emptying; azithromycin has substantially lower motilin receptor affinity, producing fewer GI motility adverse effects
ANSWER: E
Rationale:
Macrolides, particularly erythromycin, exert their GI prokinetic effect by acting as agonists at motilin receptors. Motilin is a peptide hormone secreted by enterochromaffin-like cells of the small intestine that normally triggers the migrating motor complex (MMC) — the cyclical interdigestive contractions that clear undigested material from the stomach and small bowel between meals. Erythromycin's structural similarity to motilin allows it to bind and activate these receptors, accelerating gastric emptying even in the fasting state. This mechanism has been deliberately exploited at sub-antimicrobial doses (1 to 3 mg/kg IV or 125 to 250 mg orally) as a prokinetic agent for diabetic gastroparesis and critically ill patients with feeding intolerance. Azithromycin has substantially lower motilin receptor affinity than erythromycin, which accounts for its considerably better GI tolerability, though it is not entirely free of motility effects at therapeutic doses.
Option A: Option A is incorrect because erythromycin does not inhibit acetylcholinesterase; its GI effect is mediated through motilin receptor agonism, not cholinergic amplification.
Option B: Option B is incorrect because erythromycin does not block dopamine D2 receptors; D2 antagonism is the mechanism of prokinetic drugs such as metoclopramide and domperidone, which are distinct agents.
Option C: Option C is incorrect because 5-HT4 receptor agonism is the mechanism of cisapride and tegaserod, not macrolides; erythromycin's prokinetic effect is motilin-receptor mediated.
Option D: Option D is incorrect because erythromycin does not activate smooth muscle nitric oxide synthase; nitric oxide-mediated smooth muscle relaxation is a mechanism associated with inhibitory motor neurons of the enteric nervous system, not with macrolide antibiotics.
6. A 71-year-old man with stage 3 chronic kidney disease and gout is maintained on daily low-dose colchicine for gout prophylaxis. He develops a respiratory infection and is prescribed clarithromycin. Three days later he is hospitalized with severe nausea, vomiting, diffuse myalgia, leukopenia, and rising creatinine. Which of the following best explains the mechanism responsible for this clinical presentation?
A) Clarithromycin competitively inhibits the renal tubular secretion of colchicine by blocking organic cation transporter 2 (OCT2), reducing colchicine renal clearance and causing accumulation to toxic concentrations in patients with pre-existing renal impairment
B) Clarithromycin simultaneously inhibits CYP3A4-mediated hepatic metabolism and P-glycoprotein (P-gp)-mediated intestinal efflux of colchicine, producing a dual pharmacokinetic interaction that elevates colchicine plasma concentrations to toxic and potentially lethal levels, especially in patients with reduced renal clearance of colchicine
C) Clarithromycin directly inhibits colchicine binding to tubulin in bone marrow precursor cells, displacing colchicine from its intracellular target and redirecting free colchicine to vascular endothelium where it precipitates multi-organ ischemia
D) Clarithromycin inhibits hepatic UDP-glucuronosyltransferase (UGT) enzymes responsible for colchicine glucuronidation, reducing phase II metabolism and causing colchicine to accumulate in the renal tubular epithelium, producing direct nephrotoxicity
E) Clarithromycin reduces colchicine protein binding by competing for albumin binding sites, increasing the free fraction of colchicine available to enter cells and exert toxic effects on microtubule polymerization in bone marrow and GI epithelium
ANSWER: B
Rationale:
This presentation is consistent with colchicine toxicity precipitated by a pharmacokinetic drug interaction with clarithromycin. Colchicine has a narrow therapeutic index and relies on two major pathways to limit systemic accumulation: hepatic CYP3A4 metabolism and P-glycoprotein (P-gp)-mediated efflux in the intestinal wall, which limits oral absorption. Clarithromycin is a potent inhibitor of both CYP3A4 and P-gp simultaneously. When both pathways are inhibited, colchicine absorption increases (less P-gp efflux) while hepatic clearance decreases (less CYP3A4 metabolism), producing a multiplicative rise in colchicine exposure. In this patient, pre-existing chronic kidney disease has already reduced renal clearance of colchicine, leaving him with a narrowed safety margin. The resulting toxicity manifests as the classic colchicine toxicity syndrome: severe GI toxicity (nausea, vomiting), bone marrow suppression (leukopenia), myopathy (diffuse myalgia), and nephrotoxicity — which can progress to multi-organ failure and death. This combination is contraindicated in patients with renal or hepatic impairment; azithromycin is the preferred macrolide for patients on colchicine.
Option A: Option A is incorrect because colchicine is not primarily cleared by OCT2-mediated renal tubular secretion; its renal elimination is passive, and the critical interaction involves CYP3A4 and P-gp rather than active tubular transport.
Option C: Option C is incorrect because clarithromycin does not displace colchicine from tubulin binding sites; there is no direct pharmacodynamic competition between the two drugs at the tubulin level.
Option D: Option D is incorrect because UGT inhibition is not the primary mechanism of the clarithromycin-colchicine interaction; colchicine's principal metabolic pathway is CYP3A4, not UGT glucuronidation.
Option E: Option E is incorrect because competition for albumin binding is not a clinically significant mechanism of the colchicine-clarithromycin interaction; colchicine's protein binding is moderate and displacement at albumin sites does not account for the degree of toxicity observed.
7. A pharmacology student asks why azithromycin can be given as a 5-day course or even as a single dose for some infections, while erythromycin must be dosed four times daily. Which of the following best explains the pharmacokinetic basis for azithromycin's short-course dosing regimens?
A) Azithromycin is eliminated exclusively by renal filtration with a serum half-life of 68 hours, meaning drug continues to be released from plasma proteins into tissues long after the last dose and maintains antibacterial concentrations for weeks
B) Azithromycin undergoes enterohepatic recirculation that continuously reabsorbs biliary-excreted drug from the intestine, maintaining serum concentrations above the minimum inhibitory concentration for the majority of common respiratory pathogens for 7 to 10 days after a 5-day course
C) Azithromycin binds irreversibly to the 50S ribosomal subunit of susceptible bacteria at the site of infection, so that even after serum concentrations fall below the minimum inhibitory concentration, bacteria already exposed continue to have their ribosomes permanently occupied by drug
D) Azithromycin accumulates extensively in phagocytic cells and tissues to concentrations 10 to 100 times higher than concurrent serum levels, with a tissue half-life of approximately 68 hours; this reservoir of intracellular drug maintains effective concentrations at the site of infection long after serum levels become undetectable
E) Azithromycin has a serum half-life equivalent to erythromycin but its high protein binding of greater than 95% creates a large plasma reservoir that slowly equilibrates with tissues over days to weeks, sustaining drug delivery to infected tissues
ANSWER: D
Rationale:
Azithromycin's capacity for short-course regimens is directly attributable to its unique tissue pharmacokinetics. As an azalide, azithromycin is avidly taken up by phagocytic cells — alveolar macrophages, polymorphonuclear neutrophils, monocytes, and fibroblasts — achieving intracellular concentrations 10 to 100 times higher than concurrent serum levels. The tissue half-life is approximately 68 hours, far exceeding the serum half-life of approximately 40 to 68 hours, meaning effective drug concentrations persist at sites of infection for days after each dose and for days to over a week after the final dose. This pharmacokinetic profile enables the 5-day Z-pack regimen for community-acquired respiratory infections and single-dose (1 gram) therapy for uncomplicated Chlamydia trachomatis infection. The macrophages that concentrate azithromycin also deliver it directly to sites of bacterial infection, as phagocytes migrate to areas of inflammation.
Option A: Option A is incorrect because azithromycin is not eliminated predominantly by renal filtration; it is excreted primarily as unchanged drug in bile, and the 68-hour value refers to tissue half-life, not serum half-life.
Option B: Option B is incorrect because enterohepatic recirculation is not the mechanism for azithromycin's prolonged effect; its duration is due to tissue accumulation in cells, not recirculation from bile.
Option C: Option C is incorrect because azithromycin does not bind irreversibly to bacterial ribosomes; its binding to the 23S rRNA is reversible, and the prolonged duration of effect is pharmacokinetic (tissue accumulation) rather than pharmacodynamic (irreversible target binding).
Option E: Option E is incorrect because azithromycin's protein binding is approximately 50%, not greater than 95%, and its short-course activity depends on intracellular tissue accumulation, not a plasma protein reservoir.
8. A clinical microbiology report identifies a Staphylococcus aureus isolate with MLSB (macrolide-lincosamide-streptogramin B) resistance. The house officer asks how this resistance pattern arises and why it affects three structurally distinct antibiotic classes simultaneously. Which of the following best explains the molecular mechanism and the breadth of cross-resistance?
A) The erm (erythromycin ribosome methylation) gene encodes a methylase enzyme that methylates the adenine residue at position 2058 (A2058) in the 23S rRNA of the 50S subunit — the binding site shared by macrolides, lincosamides, and streptogramin B antibiotics; this single modification reduces the affinity of all three drug classes for their shared ribosomal target simultaneously
B) The erm gene encodes a multidrug efflux pump of the ATP-binding cassette (ABC) transporter family that expels macrolides, lincosamides, and streptogramin B antibiotics from the bacterial cytoplasm; its broad substrate specificity across three antibiotic classes is due to recognition of a common structural motif present in all MLSB agents
C) The erm gene product inactivates macrolides, lincosamides, and streptogramin B antibiotics by acetylating a hydroxyl group on each drug; this modification prevents all three drug classes from entering the bacterial cell through their shared outer membrane porin channel
D) MLSB resistance results from a mutation in the rplV gene encoding the L22 ribosomal protein, which narrows the peptide exit tunnel and prevents all three drug classes from accessing their binding site within the tunnel; the same point mutation confers cross-resistance to all MLSB agents
E) The erm gene encodes a ribosome protection protein that binds directly to the 50S subunit and physically displaces macrolides, lincosamides, and streptogramin B antibiotics from the 23S rRNA after they have already bound, reversing inhibition in an ATP-dependent manner
ANSWER: A
Rationale:
MLSB resistance is predominantly mediated by erm (erythromycin ribosome methylation) genes, which encode methylase enzymes that add a methyl group to the N-6 position of the adenine residue at position 2058 (A2058) in the 23S rRNA of the 50S ribosomal subunit. This specific adenine residue sits at the core of the binding site shared by macrolides, lincosamides (such as clindamycin), and streptogramin B antibiotics. Because all three drug classes contact the same A2058 region of 23S rRNA as part of their ribosome binding, a single modification at this site reduces the affinity of all three classes simultaneously, conferring the broad cross-resistance pattern called MLSB. The erm genes are carried on plasmids and transposons, facilitating horizontal spread among streptococci, staphylococci, and enterococci. MLSB resistance can be constitutively expressed or inducibly expressed (triggered by macrolide exposure).
Option B: Option B is incorrect because the mef gene (not erm) encodes a macrolide-specific efflux pump, and that efflux mechanism confers resistance only to macrolides — not to lincosamides or streptogramin B, which are not mef substrates; the mef pump produces the M phenotype, not MLSB resistance.
Option C: Option C is incorrect because erm does not encode an acetyltransferase that modifies the drugs themselves; enzymatic drug modification is the mechanism of aminoglycoside-modifying enzymes and chloramphenicol acetyltransferase, not of macrolide resistance via erm.
Option D: Option D is incorrect because rplV mutations causing L22 ribosomal protein changes are a minor, intrinsic resistance mechanism that narrows the exit tunnel and is associated with low-level macrolide resistance in some organisms; it is not the mechanism of MLSB resistance, which is ribosomal RNA methylation.
Option E: Option E is incorrect because ribosome protection through an ATP-dependent displacement protein describes the mechanism of tetracycline resistance proteins (such as TetM and TetO), not macrolide resistance; erm methylase modifies the rRNA rather than displacing bound drug.
9. A 66-year-old woman with a history of heart failure, hypokalemia, and concurrent use of amiodarone develops a community-acquired pneumonia. Her physician is considering a macrolide antibiotic but is concerned about cardiac risk. Which of the following best explains the cardiac mechanism of macrolide-associated arrhythmia and identifies the patient characteristic most likely to amplify this risk?
A) Macrolides cause cardiac arrhythmia by inhibiting the L-type calcium channel in ventricular myocytes, reducing the plateau phase of the action potential and shortening the QT interval; this effect is most dangerous in patients with pre-existing long QT syndrome because the shortened QT increases vulnerability to re-entrant arrhythmias
B) Macrolides activate the sympathetic nervous system by blocking presynaptic alpha-2 adrenergic receptors in cardiac ganglia, increasing catecholamine release; the resulting increase in heart rate reduces the QT interval and can precipitate ventricular fibrillation in patients with coronary artery disease
C) Macrolides block the rapid component of the delayed rectifier potassium current (IKr), encoded by the hERG (human ether-a-go-go-related gene), delaying ventricular repolarization and prolonging the QT interval; concurrent hypokalemia further reduces IKr current, amplifying QT prolongation and increasing risk of torsades de pointes
D) Macrolides inhibit the slow component of the delayed rectifier potassium current (IKs) by blocking KCNQ1 channel subunits, an effect that is reversed by sympathetic stimulation; the cardiac risk is therefore highest during episodes of bradycardia when IKs cannot compensate for reduced IKr activity
E) Macrolides prolong the QT interval by inhibiting the fast sodium channel (INa) during phase 0 of the cardiac action potential, slowing ventricular depolarization; the risk is amplified in patients taking amiodarone because amiodarone independently activates INa during repolarization
ANSWER: C
Rationale:
Macrolides prolong the cardiac QT interval by blocking the rapid component of the delayed rectifier potassium current, known as IKr, which is encoded by the hERG gene. IKr is a critical repolarizing current during phase 3 of the ventricular action potential; its inhibition delays repolarization, prolongs the QT interval, and creates the conditions for early afterdepolarizations — triggered beats arising during the prolonged repolarization phase that can initiate torsades de pointes (TdP), a polymorphic ventricular tachycardia that may degenerate into ventricular fibrillation. Hypokalemia amplifies QT prolongation because extracellular potassium normally helps maintain IKr channel activity; low serum potassium reduces IKr current independently of drug effect, compounding macrolide-induced IKr block. This patient has multiple risk factors for macrolide-associated TdP: hypokalemia, amiodarone co-administration (amiodarone itself prolongs the QT interval by multiple mechanisms), heart failure, and female sex (which is an independent risk factor for drug-induced QT prolongation). A 2012 cohort study by Ray et al. published in the New England Journal of Medicine documented increased cardiovascular death rates with azithromycin compared to amoxicillin, concentrated in patients with pre-existing cardiovascular disease.
Option A: Option A is incorrect because macrolides do not inhibit L-type calcium channels, and the mechanism of concern is QT prolongation (lengthening), not QT shortening; shortened QT intervals have a different arrhythmia risk profile.
Option B: Option B is incorrect because macrolides do not block presynaptic alpha-2 adrenergic receptors; the cardiac risk is due to direct IKr channel block, not adrenergic stimulation.
Option D: Option D is incorrect because the macrolide target is IKr (hERG/KCNQ2), not IKs (KCNQ1); IKs inhibition is not the primary mechanism of macrolide QT prolongation, and the clinical risk pattern does not match an IKs-specific mechanism.
Option E: Option E is incorrect because macrolides do not prolong the QT interval by inhibiting the fast sodium channel (INa); fast sodium channel inhibition is the mechanism of class I antiarrhythmic drugs such as flecainide and quinidine, and would primarily affect phase 0 depolarization and QRS duration rather than QT interval duration.
10. A 62-year-old man with hyperlipidemia (taking simvastatin), atrial fibrillation (taking warfarin), and a recent renal transplant (taking cyclosporine) presents with an exacerbation of chronic obstructive pulmonary disease (COPD) with features consistent with atypical bacterial pneumonia. A macrolide antibiotic is clinically indicated. Which of the following represents the most appropriate macrolide choice and the most important pharmacokinetic reason for that selection?
A) Erythromycin is preferred because its shorter half-life of approximately 1.5 to 2 hours limits the duration of drug interactions compared to longer-acting alternatives; interactions with simvastatin, warfarin, and cyclosporine are transient and easily managed with temporary dose reductions
B) Clarithromycin is preferred because its active 14-hydroxy metabolite provides superior coverage of atypical organisms compared to azithromycin, and its moderate CYP3A4 inhibition can be offset by reducing simvastatin and cyclosporine doses during the treatment course
C) Any of the three major macrolides can be used safely in this patient because the drug interactions with simvastatin, warfarin, and cyclosporine are predictable and manageable with standard dose adjustments; the choice should be based entirely on spectrum of activity and local resistance patterns
D) Erythromycin is preferred for COPD exacerbations caused by atypical organisms because its four-times-daily dosing schedule provides more sustained minimum inhibitory concentration (MIC) coverage than once-daily azithromycin; the CYP3A4 interaction with cyclosporine is acceptable given the short treatment duration
E) Azithromycin is the preferred macrolide because it produces negligible CYP3A4 inhibition and does not inhibit P-glycoprotein at clinical doses, making it the safest choice in this patient taking simvastatin, warfarin, and cyclosporine — all narrow-therapeutic-index CYP3A4 substrates where elevated concentrations risk rhabdomyolysis, supratherapeutic anticoagulation, and calcineurin inhibitor nephrotoxicity respectively
ANSWER: E
Rationale:
Azithromycin is the correct choice in this complex polypharmacy patient. It produces negligible CYP3A4 inhibition because, unlike erythromycin and clarithromycin, it is not significantly demethylated by CYP3A4 and therefore does not form the inhibitory nitrosoalkane-Fe²⁺ complex that irreversibly inactivates the enzyme. All three of the patient's concurrent medications are clinically important CYP3A4 substrates: simvastatin accumulation causes myopathy and rhabdomyolysis; supratherapeutic warfarin from CYP3A4 (and CYP2C9) inhibition causes bleeding; and elevated cyclosporine concentrations from CYP3A4 inhibition cause nephrotoxicity and other calcineurin inhibitor toxicities in the transplant setting. Using erythromycin or clarithromycin in this patient would predictably elevate all three drug levels simultaneously — a situation where multiple serious adverse outcomes are simultaneously at risk. Azithromycin's atypical organism coverage (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) is fully adequate for empiric treatment of atypical CAP or COPD exacerbation caused by these pathogens.
Option A: Option A is incorrect because erythromycin's shorter serum half-life does not reduce the clinical significance of its CYP3A4 interactions; mechanism-based inhibition is persistent regardless of serum half-life because it requires new enzyme synthesis for recovery, and drug levels can rise dangerously during even a short course.
Option B: Option B is incorrect because clarithromycin is a significant CYP3A4 inhibitor; simply reducing doses of affected drugs does not reliably prevent toxicity, and this approach is particularly hazardous with cyclosporine in a transplant patient.
Option C: Option C is incorrect because the interactions are not equivalent or easily managed across all three macrolides; azithromycin's minimal CYP3A4 profile makes it categorically safer than erythromycin or clarithromycin in this specific patient.
Option D: Option D is incorrect because erythromycin's four-times-daily dosing does not provide superior MIC coverage for atypical organisms compared to azithromycin, and the CYP3A4 interaction with cyclosporine is not acceptable for any duration given the potential for calcineurin inhibitor nephrotoxicity.
11. A Streptococcus pneumoniae isolate from a patient with pneumonia is reported as resistant to erythromycin but susceptible to clindamycin by standard susceptibility testing. The clinical microbiologist explains that this pattern is consistent with the M phenotype of macrolide resistance. Which of the following best describes the M phenotype mechanism and explains why it does not confer resistance to clindamycin?
A) The M phenotype is caused by constitutive expression of erm methylase, which methylates the 23S rRNA A2058 residue only when macrolide antibiotics are present in the growth medium; because clindamycin does not induce erm expression, the 23S rRNA remains unmethylated in the absence of macrolide induction, preserving clindamycin susceptibility
B) The M phenotype is conferred by the mef (macrolide efflux) gene, which encodes a proton-dependent efflux pump specific for macrolide antibiotics; clindamycin is not a substrate for the mef pump and therefore accumulates normally within the bacterial cell to inhibit protein synthesis at the 50S subunit
C) The M phenotype results from a mutation in the 23S rRNA at position 2063 that alters the macrolide binding site without affecting the clindamycin binding site, which is located on the L22 ribosomal protein rather than the 23S rRNA; the two binding sites are structurally independent
D) The M phenotype is mediated by a plasmid-encoded cleavage enzyme that degrades the macrolide lactone ring after drug entry into the cell; clindamycin lacks a lactone ring and therefore is not a substrate for this enzyme, explaining the pattern of macrolide resistance with preserved clindamycin susceptibility
E) The M phenotype arises from overexpression of the standard outer membrane porin that serves as the entry channel for macrolides; down-regulation of this porin reduces macrolide intracellular accumulation, but clindamycin enters through a different porin unaffected by this regulatory change
ANSWER: B
Rationale:
The M phenotype of macrolide resistance is mediated by the mef (macrolide efflux) gene, which encodes a proton-motive force-dependent efflux pump that transports macrolide antibiotics out of the bacterial cytoplasm. Unlike MLSB resistance mediated by erm methylase — which modifies the shared ribosomal binding site and confers cross-resistance to macrolides, lincosamides, and streptogramin B simultaneously — the mef efflux pump is substrate-specific for macrolides. Clindamycin (a lincosamide) is not a substrate for the mef pump and is not effluxed; it therefore accumulates normally inside the bacterium and retains activity against the 50S ribosomal target. This mechanistic difference is clinically important because it means an S. pneumoniae isolate with the M phenotype may still be treated with clindamycin, whereas an isolate with MLSB resistance (erm-mediated) would be resistant to both. The M phenotype is prevalent in North American S. pneumoniae isolates and produces low-level macrolide resistance (MIC typically 1–32 mcg/mL).
Option A: Option A is incorrect because it describes inducible MLSB resistance (inducible erm), not the M phenotype; in inducible MLSB resistance, the pattern can appear as macrolide resistance with apparent clindamycin susceptibility, but the mechanism is erm methylase, not a macrolide-specific efflux pump, and the D-zone test is needed to detect inducible erm before using clindamycin.
Option C: Option C is incorrect because position 2063 23S rRNA mutations are associated with macrolide-resistant Mycoplasma pneumoniae, not the M phenotype in S. pneumoniae, and clindamycin's binding site is not exclusively on the L22 protein — it also contacts 23S rRNA.
Option D: Option D is incorrect because no clinically significant macrolide-resistance mechanism involves a lactone ring-cleaving enzyme; enzymatic drug inactivation in macrolide resistance is not a prominent clinical mechanism, and the mef pump is the basis of the M phenotype.
Option E: Option E is incorrect because S. pneumoniae is a Gram-positive organism without an outer membrane and therefore without outer membrane porins; Gram-positive efflux resistance involves cytoplasmic membrane transporters, not outer membrane porin regulation.
12. A 38-year-old previously healthy woman with no recent antibiotic use presents to an outpatient clinic with 4 days of fever, cough productive of sputum, and a patchy infiltrate on chest X-ray consistent with community-acquired pneumonia (CAP). She has no drug allergies and takes no regular medications. According to IDSA/ATS guidelines, which of the following statements best describes the role of macrolide monotherapy in this clinical scenario and the resistance threshold that determines its appropriateness?
A) Macrolide monotherapy is no longer recommended for any outpatient CAP by current IDSA/ATS guidelines because macrolide resistance among Streptococcus pneumoniae has exceeded 40% nationally; a respiratory fluoroquinolone is now the preferred empiric agent for all outpatient CAP regardless of severity or resistance data
B) Macrolide monotherapy is appropriate for this patient only if a rapid urinary antigen test confirms Streptococcus pneumoniae as the causative organism, because IDSA/ATS guidelines recommend pathogen-directed therapy rather than empiric broad-spectrum macrolide coverage for outpatient CAP
C) Macrolide monotherapy is contraindicated in outpatient CAP because macrolides do not cover Haemophilus influenzae; a beta-lactam must always be combined with a macrolide to provide dual coverage of typical and atypical pathogens in the outpatient setting
D) Macrolide monotherapy is endorsed by IDSA/ATS guidelines for outpatient CAP in low-risk patients without recent antibiotic use or risk factors for drug-resistant S. pneumoniae, provided local pneumococcal macrolide resistance rates remain below 25%; in regions where resistance exceeds this threshold, a respiratory fluoroquinolone is preferred
E) Macrolide monotherapy is appropriate in this patient regardless of local resistance rates because her young age and lack of comorbidities indicate infection with atypical organisms (Mycoplasma pneumoniae or Chlamydophila pneumoniae) rather than Streptococcus pneumoniae, and atypical organisms remain universally susceptible to macrolides
ANSWER: D
Rationale:
The IDSA/ATS consensus guidelines on CAP management endorse macrolide monotherapy as an appropriate empiric regimen for outpatient CAP in previously healthy adults without recent antibiotic use and without risk factors for drug-resistant Streptococcus pneumoniae (DRSP), provided that local pneumococcal macrolide resistance rates remain below 25%. This threshold reflects the point at which clinical failure rates on macrolide monotherapy become unacceptably high for empiric use. When local resistance rates exceed 25%, a respiratory fluoroquinolone (levofloxacin, moxifloxacin) is the preferred alternative. This patient — young, previously healthy, no recent antibiotics, low-risk CAP — is an ideal candidate for macrolide monotherapy if treated in a region with resistance below the threshold. Macrolides are chosen here because they cover both typical respiratory pathogens (S. pneumoniae is within spectrum for azithromycin and clarithromycin) and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), making them uniquely suited for empiric monotherapy in this population.
Option A: Option A is incorrect because macrolide resistance among S. pneumoniae nationally has not uniformly exceeded 40%, and IDSA/ATS guidelines continue to endorse macrolides as an option below the 25% resistance threshold; the statement overstates the resistance burden and misstates the current guideline recommendation.
Option B: Option B is incorrect because IDSA/ATS guidelines support empiric therapy without pathogen confirmation for low-risk outpatient CAP; rapid antigen testing is not required before initiating macrolide therapy in this setting.
Option C: Option C is incorrect because macrolides — particularly azithromycin and clarithromycin — do provide coverage of H. influenzae, and beta-lactam combination is not required in outpatient low-risk CAP; combination beta-lactam plus macrolide therapy is reserved for hospitalized CAP patients.
Option E: Option E is incorrect because clinical presentation does not reliably distinguish atypical from typical pathogens, atypical organisms are not the exclusive cause of CAP in young adults, and macrolide resistance in Mycoplasma pneumoniae — though less prevalent in the United States than in Asia — is increasing; assuming universal susceptibility is clinically unsound.
13. An adult patient who completed a 10-day course of erythromycin estolate two weeks ago presents with right upper quadrant pain, fever, elevated alkaline phosphatase, elevated bilirubin, and eosinophilia. Liver biopsy reveals cholestasis with periportal inflammation. Which of the following best characterizes this adverse effect, its proposed mechanism, and the clinical implication for future macrolide prescribing?
A) This presentation is consistent with erythromycin estolate-associated cholestatic hepatitis, a hypersensitivity reaction that is more common in adults than children, typically appears 10 to 20 days after starting therapy, and resolves after drug discontinuation; the estolate ester formulation has been largely withdrawn from clinical practice in many countries because of this reaction, and patients who experience it should avoid the estolate ester specifically
B) This presentation is consistent with erythromycin-associated fulminant hepatic failure, a direct hepatotoxic effect of all erythromycin formulations due to accumulation of a reactive quinone metabolite that alkylates hepatocyte mitochondrial proteins; cross-reactivity with clarithromycin and azithromycin makes the entire macrolide class contraindicated in this patient
C) This presentation is consistent with macrolide-associated autoimmune hepatitis triggered by erythromycin acting as a hapten; the drug covalently binds to CYP3A4 in hepatocytes, creating a neoantigen that stimulates a T-cell-mediated attack on hepatocytes; re-challenge with any macrolide carries a high risk of autoimmune hepatitis recurrence
D) This presentation is consistent with erythromycin-associated hepatic granulomatosis, a granulomatous reaction that is pathognomonic for macrolide hepatotoxicity; granulomas are not present with clarithromycin or azithromycin hepatotoxicity, making biopsy the definitive method for distinguishing macrolide-related from other drug-induced liver injury
E) This presentation is consistent with erythromycin-induced non-alcoholic steatohepatitis (NASH), caused by erythromycin's inhibition of mitochondrial beta-oxidation of fatty acids; eosinophilia is a characteristic feature that distinguishes this reaction from idiopathic NASH and indicates that all macrolides with CYP3A4 inhibitory activity should be avoided
ANSWER: A
Rationale:
Erythromycin estolate-associated cholestatic hepatitis is a well-established hypersensitivity reaction that presents with the classic features described: right upper quadrant pain, fever, elevated alkaline phosphatase and bilirubin, eosinophilia, and a cholestatic pattern on liver biopsy. The reaction typically appears after 10 to 20 days of therapy — consistent with the sensitization period for a hypersensitivity reaction — and resolves after discontinuation of the drug. The reaction is more common in adults than in children, a pattern opposite to most drug hypersensitivity reactions and possibly related to differences in estolate metabolism between age groups. Because of this toxicity, the erythromycin estolate formulation has been withdrawn from clinical use in many countries. The reaction is largely specific to the estolate ester and is thought to involve the propionate ester moiety, though the precise mechanism remains incompletely understood. Patients who have experienced this reaction should avoid the estolate formulation specifically; azithromycin and clarithromycin can cause hepatotoxicity at lower frequencies but tend to produce mixed or hepatocellular rather than purely cholestatic injury patterns.
Option B: Option B is incorrect because erythromycin estolate-associated hepatitis is a hypersensitivity reaction, not direct hepatotoxic fulminant liver failure, and it is not a class-wide contraindication; azithromycin and clarithromycin do not cause the same cholestatic pattern and are not contraindicated based on estolate exposure.
Option C: Option C is incorrect because erythromycin-associated hepatitis is not classified as classic autoimmune hepatitis; the reaction is a drug hypersensitivity to the estolate ester specifically, not a hapten-mediated T-cell attack on hepatocytes, and the risk does not broadly extend to all macrolides as a class.
Option D: Option D is incorrect because cholestatic hepatitis with periportal inflammation is the characteristic histological pattern of erythromycin estolate hepatotoxicity — not granulomatous inflammation; hepatic granulomas are associated with other drugs (e.g., nitrofurantoin, allopurinol) and with systemic granulomatous diseases.
Option E: Option E is incorrect because erythromycin estolate hepatitis is not caused by inhibition of mitochondrial beta-oxidation; that mechanism is characteristic of valproic acid and some nucleoside reverse transcriptase inhibitors (NRTIs), and produces microvesicular steatosis rather than the cholestatic pattern seen here.
14. A 34-year-old man with HIV infection and a CD4 (cluster of differentiation 4) T-cell count of 28 cells per microliter is not currently on antiretroviral therapy. His physician initiates prophylaxis against Mycobacterium avium complex (MAC). Which of the following correctly identifies the preferred prophylactic regimen and the reason macrolide monotherapy is acceptable for prophylaxis but not for active MAC treatment?
A) Clarithromycin 500 mg twice daily is the preferred MAC prophylaxis regimen because its active 14-hydroxy metabolite provides enhanced intracellular penetration into alveolar macrophages where MAC organisms reside; monotherapy is acceptable for prophylaxis because MAC organisms in the pre-disease state are present at too low a density to select for resistance mutations
B) Azithromycin 600 mg once daily is the preferred MAC prophylaxis regimen; monotherapy is acceptable for primary prevention because the drug is bactericidal against MAC at this dose, whereas clarithromycin is only bacteriostatic; bactericidal activity prevents the emergence of resistance that would occur with bacteriostatic agents
C) Azithromycin 1200 mg once weekly is the preferred MAC prophylaxis regimen for HIV-infected patients with CD4 counts below 50 cells per microliter; monotherapy is acceptable for primary prophylaxis because the goal is prevention of initial infection rather than eradication of established high-burden infection where macrolide resistance rapidly emerges under monotherapy selection pressure
D) Clarithromycin 1000 mg once weekly is the preferred MAC prophylaxis regimen because its 14-hydroxy metabolite has a longer tissue half-life than the parent compound, justifying once-weekly dosing; monotherapy is acceptable because clarithromycin's dual activity (parent drug plus metabolite) functionally resembles two-drug therapy
E) Azithromycin 500 mg daily for 5 days followed by 250 mg weekly is the preferred MAC prophylaxis regimen; the loading-dose strategy achieves rapid tissue saturation in alveolar macrophages that is maintained by weekly dosing; monotherapy is acceptable because azithromycin's negligible CYP3A4 inhibition means resistance does not emerge through the usual CYP3A4 induction pathway
ANSWER: C
Rationale:
For HIV-infected patients with CD4 counts below 50 cells per microliter — where the risk of disseminated MAC becomes clinically significant — azithromycin 1200 mg administered once weekly is the guideline-endorsed preferred primary prophylaxis regimen. The once-weekly schedule is feasible because azithromycin's prolonged tissue half-life of approximately 68 hours maintains intracellular concentrations in phagocytic cells for days after each weekly dose. For active MAC treatment (established disseminated disease), a macrolide must always be combined with at least ethambutol — with or without rifabutin — because macrolide monotherapy for active infection rapidly selects for high-level resistance through point mutations in the 23S rRNA gene at positions 2058 and 2059, rendering organisms resistant to the entire macrolide class. This resistance emerges because active MAC disease involves a high bacterial burden with constant replication, giving ample opportunity for spontaneous resistance mutations to be selected under monotherapy pressure. In primary prophylaxis, the goal is prevention of initial infection rather than eradication of established high-burden disease, and the bacterial exposure is insufficient to generate the sustained mutation-selection dynamic that produces clinical resistance.
Option A: Option A is incorrect because the preferred prophylaxis regimen is azithromycin 1200 mg weekly, not clarithromycin twice daily; while clarithromycin is an alternative, azithromycin is preferred for primary MAC prophylaxis. The explanation for monotherapy acceptability in prophylaxis is pharmacological (bacterial burden and selection pressure), not microbiological density alone.
Option B: Option B is incorrect because azithromycin is not bactericidal against MAC organisms at prophylactic doses; it is bacteriostatic, and the distinction between prophylaxis and treatment acceptability for monotherapy is based on bacterial burden and resistance selection dynamics, not bactericidal versus bacteriostatic activity.
Option D: Option D is incorrect because no MAC prophylaxis guideline recommends clarithromycin 1000 mg once weekly; this dose and schedule are not standard, and the 14-hydroxy metabolite's half-life does not justify weekly dosing of clarithromycin.
Option E: Option E is incorrect because no MAC prophylaxis regimen uses a loading dose followed by weekly maintenance; the standard is straightforward azithromycin 1200 mg once weekly, and azithromycin's lack of CYP3A4 inhibition has no relationship to macrolide resistance emergence in MAC.
15. A microbiology laboratory reports a Staphylococcus aureus isolate from a wound infection as resistant to erythromycin but susceptible to clindamycin by standard disk diffusion testing. The laboratory also performs a D-zone test, which returns positive. Which of the following best explains what the positive D-zone test indicates and what clinical action is appropriate?
A) A positive D-zone test indicates that the isolate produces an erm methylase constitutively; the erythromycin and clindamycin disks are placed far apart and full inhibition zones around both disks confirm constitutive MLSB resistance; the isolate should be reported as resistant to both erythromycin and clindamycin, and alternative therapy is required
B) A positive D-zone test indicates the presence of mef-mediated efflux resistance; the D-shaped zone forms because the mef pump, induced by proximity to the erythromycin disk, begins to efflux clindamycin in addition to macrolides; the isolate should be reported as having macrolide-only resistance but with potential for clindamycin failure under high-dose therapy
C) A positive D-zone test indicates that the isolate overexpresses penicillin-binding protein 2a (PBP2a), which confers methicillin resistance; the D-shape forms because beta-lactam antibiotics from the erythromycin disk compete with clindamycin for binding to the altered PBP2a, producing a blunted inhibition zone around the clindamycin disk
D) A positive D-zone test indicates constitutional susceptibility to clindamycin confirmed by two independent methods — standard MIC testing and disk diffusion — and the D-shaped inhibition zone around the clindamycin disk is the expected morphology for clindamycin against macrolide-resistant organisms; clindamycin therapy can proceed with confidence
E) A positive D-zone test indicates inducible MLSB resistance: the erythromycin disk induces erm methylase expression in the zone of subinhibitory erythromycin concentration adjacent to the clindamycin disk, blunting the clindamycin inhibition zone on the side facing erythromycin and producing a D-shaped zone; the isolate should be reported as clindamycin-resistant regardless of MIC, because in vivo selection of constitutive erm mutants can cause clindamycin treatment failure
ANSWER: E
Rationale:
The D-zone test (double-disk diffusion test) is designed to detect inducible MLSB resistance in isolates that appear susceptible to clindamycin but resistant to erythromycin on routine testing. When erythromycin and clindamycin disks are placed 15 to 26 mm apart on an agar plate, the gradient of subinhibitory erythromycin concentration radiating from the erythromycin disk induces erm methylase expression in organisms capable of inducible MLSB resistance. In the zone adjacent to the erythromycin disk, erm expression is induced; these organisms now have methylated 23S rRNA and are resistant to clindamycin as well. This produces flattening of the clindamycin inhibition zone on the side facing the erythromycin disk, creating the characteristic D-shape. A positive D-zone test indicates that although the organism appears clindamycin-susceptible in standard testing (where no erythromycin is present to induce erm), exposure to clindamycin in vivo can select for constitutive erm-expressing mutants that arise at low frequency in the inducible population, leading to clinical treatment failure. Standard practice is to report such isolates as clindamycin-resistant regardless of the MIC result.
Option A: Option A is incorrect because constitutive MLSB resistance produces complete blunting of the clindamycin inhibition zone (a flat edge, not a D-shape), and the erythromycin and clindamycin disks must be placed close enough together (15–26 mm) to allow gradient interaction — not far apart; a positive D-zone test by definition shows inducible, not constitutive, erm expression.
Option B: Option B is incorrect because mef-mediated efflux produces the M phenotype (macrolide resistance only), not inducible MLSB; the mef pump does not efflux clindamycin and is not induced by erythromycin proximity in a way that produces D-zone blunting.
Option C: Option C is incorrect because the D-zone test assesses macrolide-lincosamide resistance mechanisms, not PBP2a expression; methicillin resistance is detected by cefoxitin disk diffusion or PCR for mecA, not by erythromycin-clindamycin disk pairing.
Option D: Option D is incorrect because a positive D-zone test is not a confirmation of clindamycin susceptibility; it is the opposite — an indicator of inducible resistance that predicts possible clindamycin treatment failure and should result in reporting the organism as clindamycin-resistant.
16. A 24-year-old non-pregnant woman is diagnosed with uncomplicated urogenital Chlamydia trachomatis infection. She asks her physician why the treatment recommendation has changed from the single-dose azithromycin regimen she received two years ago. Which of the following best explains the current CDC guideline preference and the pharmacological basis for the change?
A) Single-dose azithromycin remains the CDC-preferred treatment for uncomplicated chlamydia in non-pregnant patients; the change the patient recalls reflects a transition from 500 mg to 1 gram single-dose azithromycin, driven by evidence that higher doses reduce recurrence rates in patients with concurrent Mycoplasma genitalium infection
B) Updated CDC guidelines prefer doxycycline 100 mg twice daily for 7 days over single-dose azithromycin 1 gram for uncomplicated urogenital chlamydia in non-pregnant patients, based on evidence of higher microbiologic cure rates with doxycycline, emerging azithromycin treatment failures, and concerns about resistance selection in concurrent Mycoplasma genitalium infection
C) The guideline change reflects discovery that Chlamydia trachomatis has developed widespread constitutive resistance to azithromycin through acquisition of the mef efflux gene from commensal streptococci; doxycycline remains effective because tetracyclines use a different entry pathway not affected by mef-mediated efflux
D) The change from azithromycin to doxycycline for chlamydia reflects concerns about azithromycin-associated QTc prolongation in young women, who are at higher risk for drug-induced torsades de pointes; doxycycline does not prolong the QTc interval and is therefore preferred for this demographic
E) Single-dose azithromycin was replaced because its prolonged tissue half-life of 68 hours creates a subinhibitory concentration window during drug washout that preferentially selects for macrolide-resistant Neisseria gonorrhoeae co-infection; doxycycline provides simultaneous coverage of both Chlamydia trachomatis and gonorrhea and eliminates this resistance selection concern
ANSWER: B
Rationale:
Updated CDC sexually transmitted infection treatment guidelines (2021 and subsequent updates) shifted the preferred treatment for uncomplicated urogenital Chlamydia trachomatis infection in non-pregnant patients from azithromycin 1 gram as a single oral dose to doxycycline 100 mg twice daily for 7 days. This change was driven by accumulating evidence of higher microbiologic cure rates with doxycycline compared to single-dose azithromycin in clinical studies, particularly for rectal chlamydial infections. Additionally, rising minimum inhibitory concentrations for azithromycin against Mycoplasma genitalium — a co-infecting sexually transmitted pathogen — raised concerns that single-dose azithromycin for chlamydia was simultaneously driving macrolide resistance in M. genitalium, complicating future treatment of that organism. Azithromycin 1 gram remains the preferred regimen for chlamydia in pregnancy, where tetracyclines are contraindicated due to effects on fetal bone and tooth development.
Option A: Option A is incorrect because the CDC guideline preference has shifted to doxycycline as first-line, not to a higher dose of azithromycin; the change is a class shift, not a dose adjustment within the macrolide class.
Option C: Option C is incorrect because Chlamydia trachomatis has not developed widespread mef-mediated azithromycin resistance; C. trachomatis is an obligate intracellular organism with no documented acquisition of mef from streptococcal commensals, and the guideline change is based on comparative clinical efficacy, not documented mef resistance mechanisms.
Option D: Option D is incorrect because QTc prolongation concerns were not the primary driver of the guideline shift from azithromycin to doxycycline for chlamydia; the change was based on microbiologic cure data and M. genitalium resistance concerns, and QTc risk from a single 1-gram dose of azithromycin in healthy young women without cardiac risk factors is not the reason for the recommendation change.
Option E: Option E is incorrect because the concern driving the guideline change relates to M. genitalium resistance selection, not Neisseria gonorrhoeae; gonorrhea is no longer treated with macrolides at all due to widespread resistance, and doxycycline is not the preferred treatment for gonorrhea either.
17. A hospitalized patient with pneumococcal pneumonia and concurrent bacteremia is being managed by the internal medicine team. A medical student suggests switching from ceftriaxone to azithromycin because "azithromycin achieves such high tissue concentrations." The attending physician disagrees. Which of the following best explains why azithromycin's tissue accumulation does not make it appropriate monotherapy for bloodstream infection?
A) Azithromycin is contraindicated in bacteremia because its irreversible binding to bacterial ribosomes causes rapid lysis of circulating bacteria, releasing endotoxin and precipitating septic shock; parenteral beta-lactams must always be used for bacteremia to avoid this bactericidal overshoot
B) Azithromycin accumulates in tissues but is actively excluded from plasma by P-glycoprotein transporters on endothelial cells lining blood vessels; plasma concentrations therefore remain below minimum inhibitory concentrations for bacteremic pathogens regardless of tissue levels, making it pharmacokinetically unsuitable for bacteremia
C) Azithromycin is not licensed by the FDA for intravenous administration, and oral azithromycin is not absorbed from the GI tract during bacteremic illness because sepsis-associated ileus prevents intestinal drug absorption in all patients with bloodstream infection
D) Azithromycin's high tissue accumulation is achieved at the expense of low serum concentrations — substantially lower than concurrent tissue levels — making serum drug concentrations unreliable for killing bacteria circulating in the bloodstream, where tissue-level drug reservoir concentrations are unavailable to act
E) Azithromycin rapidly distributes out of plasma into tissues within minutes of administration, leaving bacteremic organisms in the bloodstream transiently exposed to extremely high peak drug concentrations that are paradoxically bacteriostatic rather than bactericidal, allowing bacteremia to persist despite adequate tissue levels
ANSWER: D
Rationale:
Azithromycin's unique pharmacokinetic profile — tissue concentrations 10 to 100 times higher than concurrent serum levels — is a major clinical advantage for infections in tissues where phagocytes deliver the drug, but it is a significant limitation for bloodstream infections. Bacteria circulating in the plasma encounter serum concentrations of azithromycin, not tissue concentrations. Because serum concentrations are substantially lower than tissue levels, and because the therapeutic efficacy of an antibiotic against bacteremia depends on maintaining adequate drug concentrations in the blood compartment where the organisms reside, azithromycin's serum levels are insufficient for reliable treatment of pneumococcal bacteremia or other bloodstream infections. This is why parenteral beta-lactams (ceftriaxone, ampicillin-sulbactam) remain the cornerstone of bacteremic pneumococcal infection management, and macrolides — when added — are combined with beta-lactams rather than used as monotherapy.
Option A: Option A is incorrect because azithromycin is not a bactericidal agent that causes rapid bacterial lysis; it is bacteriostatic for most organisms, including S. pneumoniae, and does not produce the endotoxin-release concern associated with rapid lysis by bactericidal agents.
Option B: Option B is incorrect because azithromycin is not actively excluded from plasma by P-glycoprotein on vascular endothelium in the direction described; while P-gp does affect azithromycin intestinal absorption, the low serum levels are a consequence of avid tissue uptake from plasma, not active exclusion from the bloodstream by P-gp.
Option C: Option C is incorrect because azithromycin is available in both intravenous and oral formulations, and the assertion that oral absorption is universally abolished by sepsis-associated ileus in all bacteremic patients is incorrect; absorption varies, and IV azithromycin exists as an option; however, the fundamental issue is serum concentration inadequacy, not the route of administration.
Option E: Option E is incorrect because azithromycin does not produce paradoxical bacteriostatic activity from high peak concentrations; bacteriostatic versus bactericidal activity is a property of the mechanism of action, and concentration-dependent bactericidal "paradox" is associated with beta-lactams at very high doses in some organisms, not with macrolides.
18. A pharmacist counseling a patient newly prescribed clarithromycin for a respiratory tract infection explains that clarithromycin's hepatic metabolism produces an active metabolite that contributes to its antibacterial spectrum. Which of the following best identifies this metabolite, its activity, and why this metabolic pathway is clinically significant for respiratory infections?
A) Clarithromycin is metabolized hepatically to 14-hydroxyclarithromycin, an active metabolite that has antibacterial activity against Haemophilus influenzae in particular; this metabolite extends clarithromycin's effective spectrum compared to erythromycin and contributes to its utility in respiratory infections where H. influenzae is a common pathogen
B) Clarithromycin is metabolized to a nitrosoalkane-iron complex that retains full antibacterial activity against atypical respiratory pathogens while simultaneously and irreversibly inhibiting CYP3A4; this metabolite is responsible for both clarithromycin's enhanced spectrum and its drug interaction profile
C) Clarithromycin is demethylated by CYP3A4 to N-desmethylclarithromycin, which is the active form responsible for all antibacterial activity; the parent compound itself is pharmacologically inert and serves only as a prodrug to improve oral bioavailability compared to the active metabolite alone
D) Clarithromycin undergoes ester hydrolysis in the intestinal wall to release free erythromycin, which is the pharmacologically active species; the ester prodrug strategy was developed to improve the acid stability of erythromycin during oral delivery, and clarithromycin has no antibacterial activity distinct from its erythromycin metabolite
E) Clarithromycin is metabolized in the liver to an epoxide intermediate that alkylates bacterial DNA gyrase at the same site as fluoroquinolones, providing dual mechanism antibacterial activity against both macrolide-susceptible and fluoroquinolone-susceptible respiratory pathogens when given at full therapeutic doses
ANSWER: A
Rationale:
Clarithromycin is a 6-O-methyl derivative of erythromycin that undergoes hepatic metabolism to its primary active metabolite, 14-hydroxyclarithromycin. This metabolite retains antibacterial activity and importantly demonstrates activity against Haemophilus influenzae, extending the effective spectrum of clarithromycin beyond that of erythromycin in respiratory tract infections where H. influenzae is a frequent pathogen, particularly in acute exacerbations of chronic obstructive pulmonary disease (COPD) and sinusitis. Erythromycin has limited reliable activity against H. influenzae, making clarithromycin's metabolite-mediated H. influenzae coverage a meaningful clinical distinction. Clarithromycin also achieves oral bioavailability of approximately 50 to 55% with twice-daily dosing, improving on erythromycin's variable formulation-dependent absorption.
Option B: Option B is incorrect because the nitrosoalkane-iron complex described is the CYP3A4 inhibitory species formed during clarithromycin metabolism, not a bacterially active antibiotic metabolite; it is responsible for the drug interaction profile, not for antibacterial spectrum extension.
Option C: Option C is incorrect because 14-hydroxyclarithromycin — not N-desmethylclarithromycin — is the active metabolite of clarithromycin, and the parent compound itself has significant antibacterial activity; clarithromycin is not a prodrug in the classic sense.
Option D: Option D is incorrect because clarithromycin is not an ester prodrug of erythromycin; clarithromycin is a chemically distinct semi-synthetic macrolide (6-O-methylation changes its properties substantially), and it does not hydrolyze to release erythromycin as the active moiety.
Option E: Option E is incorrect because no macrolide metabolite is known to alkylate bacterial DNA gyrase or act through a fluoroquinolone-like mechanism; macrolides act exclusively through ribosomal 50S subunit binding and protein synthesis inhibition, not through DNA gyrase inhibition.
19. A patient with disseminated Mycobacterium avium complex (MAC) infection is started on clarithromycin monotherapy by an outpatient provider who was unaware of current combination treatment guidelines. Four weeks later the patient's symptoms worsen and repeat cultures grow MAC organisms with high-level clarithromycin resistance. Which of the following best explains the molecular mechanism of resistance that emerged and why combination therapy is required for active MAC treatment?
A) The MAC organisms acquired the erm methylase gene through horizontal transfer from co-infecting Streptococcus pneumoniae during the treatment course; combination therapy prevents this gene transfer by eliminating S. pneumoniae reservoirs before erm transfer can occur
B) The MAC organisms developed mef efflux pump overexpression under clarithromycin selection pressure; combination with ethambutol prevents this because ethambutol inhibits the efflux pump promoter region through interference with mycobacterial cell wall lipid synthesis
C) Clarithromycin monotherapy for active MAC infection rapidly selects for pre-existing spontaneous point mutations in the 23S rRNA gene at positions 2058 and 2059 — the macrolide binding site — because the high bacterial burden in disseminated MAC provides a large mutant population from which resistant organisms are selected under drug pressure; combination therapy with ethambutol and/or rifabutin prevents this selection by providing additional bactericidal mechanisms that suppress the emergence and expansion of resistant mutants
D) The MAC organisms developed resistance through adaptive upregulation of the mycobacterial intrinsic efflux system MmpL (mycobacterial membrane protein large); clarithromycin monotherapy induces MmpL expression in a dose-dependent fashion, and MmpL efflux is so efficient that standard clarithromycin doses are insufficient to maintain minimum inhibitory concentrations above the MmpL-adjusted threshold
E) Clarithromycin resistance in MAC emerged because the 14-hydroxyclarithromycin active metabolite competitively inhibits the parent compound at the 50S binding site; the metabolite-to-parent ratio increases over time due to CYP3A4 autoinduction by clarithromycin, and when metabolite concentrations exceed parent compound concentrations, the net effect at the ribosomal binding site becomes antagonistic, selecting for organisms with high-level resistance
ANSWER: C
Rationale:
Macrolide monotherapy for active disseminated MAC infection is contraindicated because it reliably selects for high-level macrolide resistance. The mechanism involves point mutations in the 23S rRNA gene at positions 2058 and 2059, which constitute the core of the macrolide binding site in the 50S ribosomal subunit. In a patient with disseminated MAC — a condition involving very high mycobacterial burden across multiple tissues — the large population of replicating organisms generates spontaneous mutations at a predictable frequency. Under macrolide monotherapy, organisms with 23S rRNA mutations at positions 2058 or 2059 have a strong selective advantage and rapidly expand to dominate the population, producing high-level resistance (MIC typically exceeding 256 mcg/mL) that renders the organism resistant to the entire macrolide class. Combination therapy with ethambutol (and optionally rifabutin) prevents this by providing bactericidal activity through independent mechanisms, suppressing overall mycobacterial replication and reducing the probability that a mutant organism will survive and expand under macrolide pressure. This is analogous to the rationale for multi-drug regimens in tuberculosis — the higher the bacterial burden, the greater the imperative for combination therapy to prevent resistance selection.
Option A: Option A is incorrect because erm gene transfer from S. pneumoniae to MAC organisms is not a recognized mechanism of clarithromycin resistance in MAC; MAC organisms are phylogenetically distant from streptococci, and horizontal erm gene transfer between these organisms has not been documented as a clinical resistance pathway.
Option B: Option B is incorrect because mef efflux pumps are not a clinically significant resistance mechanism in MAC; MAC resistance to macrolides occurs through 23S rRNA point mutations, not mef efflux, and ethambutol's mechanism involves inhibition of arabinogalactan synthesis in the mycobacterial cell wall, not efflux pump promoter inhibition.
Option D: Option D is incorrect because MmpL protein overexpression is not the primary mechanism of acquired macrolide resistance in MAC; 23S rRNA mutations are the dominant clinical resistance mechanism, and the relationship between MmpL regulation and macrolide resistance does not follow the dose-dependent induction pattern described.
Option E: Option E is incorrect because 14-hydroxyclarithromycin does not antagonize the parent compound at the 50S binding site, and clarithromycin does not induce CYP3A4 in a way that generates an antagonistic metabolite-to-parent ratio; clarithromycin is actually a CYP3A4 inhibitor, not an inducer.
20. A clinical pharmacologist explains that erythromycin's CYP3A4 inhibition is mechanistically distinct from competitive inhibition and has important implications for the duration of drug interactions after erythromycin is discontinued. Which of the following best describes this mechanism and its clinical consequence?
A) Erythromycin is a reversible competitive inhibitor of CYP3A4, occupying the enzyme active site while the drug is present in systemic circulation; because erythromycin's half-life is approximately 1.5 to 2 hours, CYP3A4 activity is fully restored within 8 to 12 hours of the last erythromycin dose, making any interaction brief and manageable
B) Erythromycin activates the pregnane X receptor (PXR) nuclear transcription factor, which upregulates CYP3A4 transcription and increases the amount of CYP3A4 enzyme in hepatocytes; this induction effect persists for 1 to 2 weeks after erythromycin is stopped, because new enzyme synthesis is required to return CYP3A4 to baseline levels
C) Erythromycin reversibly inhibits CYP3A4 by forming a tight but non-covalent complex with the enzyme's heme iron group; the complex dissociates slowly over 24 to 48 hours after erythromycin is discontinued, producing a moderate residual drug interaction risk for approximately 2 days after the antibiotic course ends
D) Erythromycin is primarily a CYP2C9 inhibitor rather than a CYP3A4 inhibitor; its drug interactions with warfarin are mediated through CYP2C9, while its interactions with simvastatin and cyclosporine are mediated through inhibition of P-glycoprotein efflux transporters rather than cytochrome P450 enzymes
E) Erythromycin undergoes metabolism by CYP3A4 to a nitrosoalkane intermediate that forms a stable, inactive complex with the ferrous (Fe²⁺) form of the enzyme; this mechanism-based inhibition is irreversible, permanently inactivating each CYP3A4 molecule it encounters and requiring de novo synthesis of new CYP3A4 protein for recovery of enzyme activity
ANSWER: E
Rationale:
Erythromycin is a prototypical mechanism-based (also called suicide or irreversible) inhibitor of CYP3A4. The inhibition occurs because erythromycin is first metabolized by CYP3A4 to a reactive nitrosoalkane intermediate, which then forms a stable coordinate complex with the ferrous (Fe²⁺) form of the CYP3A4 heme iron, permanently inactivating that enzyme molecule. Because the inhibition is irreversible, recovery of CYP3A4 activity after erythromycin is stopped does not depend on drug elimination — it depends entirely on the rate of new CYP3A4 enzyme synthesis in hepatocytes, which takes days. This means that even after erythromycin serum concentrations become undetectable, CYP3A4 capacity remains reduced until newly synthesized enzyme replaces the inactivated molecules. Clinically, this creates an important window after erythromycin discontinuation during which drug interactions with CYP3A4 substrates — statins, cyclosporine, tacrolimus, warfarin, colchicine — persist. Clarithromycin inhibits CYP3A4 by the same mechanism-based pathway, whereas azithromycin does not form this inhibitory complex.
Option A: Option A is incorrect because erythromycin is not a reversible competitive inhibitor of CYP3A4; its mechanism-based inhibition is fundamentally different from competitive inhibition in that the inhibitory effect persists well beyond clearance of the drug from plasma, not for 8 to 12 hours.
Option B: Option B is incorrect because erythromycin is a CYP3A4 inhibitor, not an inducer; PXR activation and CYP3A4 upregulation are the mechanism of rifampin, dexamethasone, and other inducers — not erythromycin.
Option C: Option C is incorrect because erythromycin's inhibition is not a slowly reversible tight complex; it is a covalent-like irreversible complex with the heme iron that requires enzyme replacement, not passive dissociation over 24 to 48 hours.
Option D: Option D is incorrect because erythromycin is primarily recognized as a CYP3A4 inhibitor (not CYP2C9), and while it does inhibit P-gp, its interaction with simvastatin is primarily CYP3A4-mediated; the characterization in this option misassigns the primary inhibited enzyme.
21. A 55-year-old man on long-term simvastatin therapy for hyperlipidemia is prescribed clarithromycin for a Helicobacter pylori eradication regimen. Which of the following best describes the pharmacokinetic interaction between clarithromycin and simvastatin, and identifies the safest statin management approach during the clarithromycin course?
A) Clarithromycin inhibits the organic anion transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter for simvastatin; the interaction is mild and managed by halving the simvastatin dose during the clarithromycin course, after which the original dose can be resumed without any washout period
B) Clarithromycin inhibits CYP3A4-mediated hepatic metabolism of simvastatin (and lovastatin), causing simvastatin plasma concentrations to rise to levels that can precipitate myopathy and rhabdomyolysis; the safest approach is to temporarily hold simvastatin and substitute rosuvastatin or pravastatin — statins that are not CYP3A4 substrates — during the clarithromycin course
C) Simvastatin inhibits clarithromycin metabolism by competing for CYP3A4 binding sites, reducing clarithromycin clearance and increasing clarithromycin concentrations to levels that amplify QTc prolongation risk; the H. pylori regimen should be modified to substitute azithromycin for clarithromycin when simvastatin cannot be discontinued
D) Clarithromycin displaces simvastatin from plasma albumin binding sites, tripling the free fraction of simvastatin available for tissue uptake; the interaction is most severe in patients with hypoalbuminemia and is managed by monitoring creatine kinase (CK) levels weekly during the treatment course without dose modification
E) Clarithromycin and simvastatin both prolong the QTc interval through independent mechanisms — clarithromycin through IKr block and simvastatin through calcium channel inhibition — and their combination produces additive QTc prolongation exceeding 60 milliseconds; the primary concern is cardiac arrhythmia rather than myopathy, and an ECG should be obtained before starting the regimen
ANSWER: B
Rationale:
Simvastatin and lovastatin are among the statins most dependent on CYP3A4 for their hepatic metabolism. Clarithromycin is a potent mechanism-based CYP3A4 inhibitor, and co-administration substantially reduces CYP3A4-mediated first-pass and systemic metabolism of simvastatin, causing plasma and tissue concentrations to accumulate to levels that risk skeletal muscle toxicity — myopathy and, at higher exposures, rhabdomyolysis (massive muscle breakdown with myoglobinuria and risk of acute kidney injury). The safest management is to hold simvastatin during the clarithromycin course and substitute a statin that is not a CYP3A4 substrate: rosuvastatin (metabolized primarily by CYP2C9 and excreted partially unchanged) and pravastatin (not significantly metabolized by CYP enzymes, largely excreted unchanged) are the preferred alternatives, as their concentrations are not meaningfully affected by CYP3A4 inhibition. Atorvastatin is a partial CYP3A4 substrate and carries intermediate risk; simvastatin and lovastatin carry the highest risk and should be held.
Option A: Option A is incorrect because OATP1B1 transporter inhibition is the mechanism of rosuvastatin and pravastatin interactions with gemfibrozil and cyclosporine, not the primary mechanism of the clarithromycin-simvastatin interaction, which is CYP3A4 mediated; simply halving the simvastatin dose does not reliably prevent rhabdomyolysis.
Option C: Option C is incorrect because simvastatin does not inhibit clarithromycin metabolism to a clinically significant degree; simvastatin is a CYP3A4 substrate (not a potent inhibitor), and the interaction is unidirectional — clarithromycin inhibits simvastatin metabolism, not vice versa.
Option D: Option D is incorrect because clarithromycin does not displace simvastatin from albumin binding in a clinically significant manner; the interaction is enzyme-mediated, not protein-binding displacement, and protein-binding displacement interactions rarely cause clinically significant toxicity in practice because plasma volume distribution adjustments occur.
Option E: Option E is incorrect because simvastatin does not prolong the QTc interval through calcium channel inhibition; statins as a class are not QTc-prolonging agents, and the primary concern with the clarithromycin-simvastatin interaction is myopathy and rhabdomyolysis, not cardiac arrhythmia.
22. A patient prescribed azithromycin immediate-release tablets for community-acquired pneumonia asks her pharmacist whether she should take the medication with food to reduce stomach upset, as she does with her clarithromycin. The pharmacist explains that the two drugs have different food instructions. Which of the following best explains the pharmacological basis for this difference and correctly characterizes azithromycin's GI tolerability compared to the other major macrolides?
A) Azithromycin immediate-release tablets should be taken with food because food increases azithromycin bioavailability by stimulating bile secretion that facilitates intestinal absorption of this lipophilic drug; GI tolerability is similar across all three major macrolides because all are equally potent motilin receptor agonists
B) Azithromycin immediate-release tablets should be taken with a full glass of milk because calcium in dairy products chelates gastric acid and stabilizes the azithromycin lactone ring against acid degradation, which would otherwise reduce bioavailability to less than 10%; this requirement distinguishes azithromycin from erythromycin, which is fully acid-stable
C) Azithromycin and clarithromycin should both be taken with food, because food reduces the rate of gastric emptying and prolongs the time available for small intestinal absorption of both agents; azithromycin's instructions otherwise identical to clarithromycin because both are acid-stable macrolides with similar absorption characteristics
D) Azithromycin immediate-release tablets should be taken on an empty stomach for optimal absorption because food reduces azithromycin bioavailability; azithromycin has the best GI tolerability of the three major macrolides because it has substantially lower motilin receptor affinity than erythromycin, and motilin receptor agonism — not direct mucosal irritation — is the primary mechanism of macrolide-associated GI adverse effects
E) Azithromycin immediate-release tablets must be taken on an empty stomach because food irreversibly denatures the azithromycin molecule through the Maillard reaction between the lactone ring carbonyl and dietary amino acids; the resulting degradation products are the primary cause of GI adverse effects with this drug class
ANSWER: D
Rationale:
Azithromycin immediate-release tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after eating), because food reduces azithromycin bioavailability — specifically, a high-fat meal has been shown to reduce the peak serum concentration (Cmax) of azithromycin oral suspension and tablets. This is in contrast to clarithromycin, which can be taken with or without food, and erythromycin, which may have variable effects with food depending on formulation. Despite its fasting requirement, azithromycin has significantly better GI tolerability than erythromycin, and better tolerability than clarithromycin as well. The primary mechanism of macrolide-associated GI adverse effects — nausea, vomiting, cramping, diarrhea — is pharmacological agonism of motilin receptors in the GI tract, not direct mucosal irritation. Erythromycin is the most potent motilin receptor agonist among the three macrolides, explaining its greatest GI intolerance burden; azithromycin has substantially lower motilin receptor affinity, producing fewer GI motility adverse effects despite its oral administration. This motilin-agonist mechanism also explains why erythromycin's GI effects are dose-dependent and exploitable therapeutically at sub-antimicrobial doses for gastroparesis.
Option A: Option A is incorrect because azithromycin immediate-release should be taken on an empty stomach, not with food; and the three macrolides differ substantially in motilin receptor affinity and GI tolerability, with erythromycin being the most potent motilin agonist and azithromycin the least.
Option B: Option B is incorrect because azithromycin does not require calcium chelation of gastric acid for stability; azithromycin is more acid-stable than erythromycin (a major advantage of its azalide ring structure), and dairy products do not play a role in azithromycin absorption optimization.
Option C: Option C is incorrect because azithromycin immediate-release tablets should be taken on an empty stomach, not with food; this distinguishes azithromycin from clarithromycin, which may be taken with or without food.
Option E: Option E is incorrect because food does not denature azithromycin through a Maillard reaction; the lactone ring does not undergo carbonyl-amino Maillard chemistry under physiological conditions, and this is not a recognized mechanism of macrolide GI effects or food interactions.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.